Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses.
Ghader MohammadnezhadHadi EsmailyMaryam TalebiMatin JafariPublished in: Journal of gastrointestinal cancer (2024)
The ATZ/BVC combination is an expensive targeted immunotherapy in AHCC. Significant discounts in ATZ and BVC prices are essential for this novel approach to be cost-effective and extensively used.